Heterotopic Ossification
14
1
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.1%
1 terminated out of 14 trials
87.5%
+1.0% vs benchmark
7%
1 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (14)
Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip Arthroplasty
Heterotopic Ossification Prophylaxis
Comparative Analysis of Radiotherapeutic and Medical Procedures for the Prophylaxis of Heterotopic Ossifications
Tranexamic Acid Prophylaxis for Heterotopic Ossification in Elbow Fracture-Dislocation Surgery
Early Ultrasound Screening of Heterotopic Ossification After Severe Neurological Trauma
Celebrex and HO Study
Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy
Defining the Pathophysiology of Heterotopic Ossification: A Prospective Study
HO Prophylaxis Therapy for Distal Humerus Fractures
Balance in Patients With Ectopic Bone Tissue After Total Hip Replacement
Uncemented Hemiarthroplasty, Radiological Features Comparing Lateral Versus Anterolateral Approach
Assessment of Heterotopic Ossification of Elbow Joint in Relation of Serum Uric Acid.
Study of Pamidronate for the Prevention of Heterotopic Ossification
Naproxen for the Prevention of HO After Complex Elbow Trauma